<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01780636</url>
  </required_header>
  <id_info>
    <org_study_id>ALLERGAN-72570</org_study_id>
    <nct_id>NCT01780636</nct_id>
  </id_info>
  <brief_title>Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome</brief_title>
  <official_title>Ultrasound and EMG Guided Botox Injection for the Treatment of Non-Relaxing Puborectalis Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Irvine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>American Urogynecologic Society</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Irvine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non-relaxing puborectalis syndrome (NRPS) is an obstructive defecatory disorder that presents
      with chronic constipation, anismus, or a sensation of incomplete rectal emptying. The
      specific etiology of this syndrome is unknown. The true incidence of NRPS is unknown, but it
      is estimated that 4% of patients with defecatory disorders have NRPS. Previous therapies for
      non-relaxing PRS have included biofeedback, pelvic floor physical therapy, dietary changes,
      laxatives, enemas, and surgical division of the puborectalis muscle. Unfortunately, responses
      to these treatments have been variable at best. Direct injection of botulinum toxin (Botox)
      into the puborectalis muscle is an alternative approach for treating NRPS and has recently
      been reported in a limited number of studies. Botox blocks cholinergic nerve endings in the
      autonomic nervous system and has been used to weaken the puborectalis muscle in constipated
      patients.

      Our study aims to determine the efficacy of ultrasound and EMG guided Botox injections into
      the puborectalis muscle in women with NRPS. With use of this technique, we believe we will
      find that Botox injections decrease symptom severity and improve quality of life (QOL) in
      patients with NRPS.

      We plan to compare patient reported symptoms, symptom severity, and QOL prior to Botox
      injections with symptoms and QOL at 2-week, 3-month, and 6-month intervals after Botox
      injection into the puborectalis muscle in patients with NRPS.

      All enrolled patients will receive ultrasound and EMG guided Botox injections at three points
      along the puborectalis muscle. Post-injection data will be obtained with a defecation diary
      and questionnaire data at the 2-week, 3-month, and 6-month intervals. Additional injections
      will be offered to patients who fail the initial treatment.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in symptoms based on scores using the PAC-SYM and Wexner Constipation questionnaires.</measure>
    <time_frame>Baseline to 6 months post-injection</time_frame>
    <description>To assess whether Botox injections into the puborectalis muscle will improve patient's symptoms based on scores using the PAC-SYM and Wexner Constipation validated questionnaires at baseline, 2 weeks, 3 months, and 6 months post-Botox injection to determine severity of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in pressures on anal manometry</measure>
    <time_frame>Baseline to 3 months post-injection</time_frame>
    <description>To assess the change in pressures on anal manometry before and after Botox injections into the puborectalis muscle at baseline and 3 months post-Botox injection.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in quality of life based on scores using the PAC-QOL questionnaire.</measure>
    <time_frame>Baseline to 6 months post-Botox injection</time_frame>
    <description>To assess whether Botox injections into the puborectalis muscle will improve patient's quality of life based on scores using the PAC-QOL validated questionnaire at 2 weeks, 3 months, and 6 months post-Botox injection.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the anorectal angle during defecation using defecography</measure>
    <time_frame>Baseline to 3 months post-injection</time_frame>
    <description>To assess the change in the anorectal angle during defecation using defecography at baseline and 3 months after Botox injections into the puborectalis muscle</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Non-relaxing Puborectalis Syndrome</condition>
  <arm_group>
    <arm_group_label>Botulinum toxin (Botox) injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will be given the active Botox injection and thus this study will remain open-label and non-randomized as this is a pilot study to determine initial efficacy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>botulinum toxin</intervention_name>
    <arm_group_label>Botulinum toxin (Botox) injection</arm_group_label>
    <other_name>Botox (Allergan, Irvine, CA)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female

          -  18 years of age or older

          -  Diagnosis of non-relaxing puborectalis syndrome

        Exclusion Criteria:

          -  Allergy or sensitivity to botulinum toxin

          -  Pregnancy or plan to become pregnant in the subsequent 6 months after injection

          -  Undiagnosed ano-rectal mass, lesion, or infection

          -  Stage II or greater rectocele
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Karen Noblett, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Irvine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony Gaddi, MD</last_name>
    <phone>714-456-8564</phone>
    <email>tgaddi@uci.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Samantha Reiter, MS</last_name>
    <phone>714-456-6846</phone>
    <email>reiters@uci.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of California, Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Karen Noblett, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anthony Gaddi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Felicia Lane, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stephanie Jacobs, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lauren Cadish, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Allison Serra, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.augs.org/</url>
    <description>American Urogynecologic Society</description>
  </link>
  <reference>
    <citation>Times ML, Reickert CA. Functional anorectal disorders. Clin Colon Rectal Surg. 2005 May;18(2):109-15. doi: 10.1055/s-2005-870892.</citation>
    <PMID>20011350</PMID>
  </reference>
  <reference>
    <citation>WASSERMAN IF. PUBORECTALIS SYNDROME (RECTAL STENOSIS DUE TO ANORECTAL SPASM). Dis Colon Rectum. 1964 Mar-Apr;7:87-98.</citation>
    <PMID>14128302</PMID>
  </reference>
  <reference>
    <citation>Kuijpers HC, Bleijenberg G. The spastic pelvic floor syndrome. A cause of constipation. Dis Colon Rectum. 1985 Sep;28(9):669-72.</citation>
    <PMID>4053909</PMID>
  </reference>
  <reference>
    <citation>Karlbom U, Hållden M, Eeg-Olofsson KE, Påhlman L, Graf W. Results of biofeedback in constipated patients: a prospective study. Dis Colon Rectum. 1997 Oct;40(10):1149-55.</citation>
    <PMID>9336109</PMID>
  </reference>
  <reference>
    <citation>Meunier P, Marechal JM, de Beaujeu MJ. Rectoanal pressures and rectal sensitivity studies in chronic childhood constipation. Gastroenterology. 1979 Aug;77(2):330-6.</citation>
    <PMID>447047</PMID>
  </reference>
  <reference>
    <citation>MacDonald A, Shearer M, Paterson PJ, Finlay IG. Relationship between outlet obstruction constipation and obstructed urinary flow. Br J Surg. 1991 Jun;78(6):693-5.</citation>
    <PMID>2070237</PMID>
  </reference>
  <reference>
    <citation>Mellgren A, Bremmer S, Johansson C, Dolk A, Udén R, Ahlbäck SO, Holmström B. Defecography. Results of investigations in 2,816 patients. Dis Colon Rectum. 1994 Nov;37(11):1133-41. Review.</citation>
    <PMID>7956583</PMID>
  </reference>
  <reference>
    <citation>Wexner SD, Jorge JM. Colorectal physiological tests: use or abuse of technology? Eur J Surg. 1994 Mar;160(3):167-74.</citation>
    <PMID>8003569</PMID>
  </reference>
  <reference>
    <citation>Halligan S, Malouf A, Bartram CI, Marshall M, Hollings N, Kamm MA. Predictive value of impaired evacuation at proctography in diagnosing anismus. AJR Am J Roentgenol. 2001 Sep;177(3):633-6.</citation>
    <PMID>11517060</PMID>
  </reference>
  <reference>
    <citation>Salzano A, Cavallo G, De Rosa A, De Luca LE, Serpe A, Losco M. [Diagnosis with defecography of puborectal muscle syndrome]. Radiol Med. 1997 Apr;93(4):396-400. Italian.</citation>
    <PMID>9244917</PMID>
  </reference>
  <reference>
    <citation>Ganeshan A, Anderson EM, Upponi S, Planner AC, Slater A, Moore N, D'Costa H, Bungay H. Imaging of obstructed defecation. Clin Radiol. 2008 Jan;63(1):18-26. Epub 2007 Sep 14. Review.</citation>
    <PMID>18068787</PMID>
  </reference>
  <reference>
    <citation>Maria G, Brisinda G, Bentivoglio AR, Cassetta E, Albanese A. Botulinum toxin in the treatment of outlet obstruction constipation caused by puborectalis syndrome. Dis Colon Rectum. 2000 Mar;43(3):376-80.</citation>
    <PMID>10733120</PMID>
  </reference>
  <reference>
    <citation>Maria G, Cadeddu F, Brandara F, Marniga G, Brisinda G. Experience with type A botulinum toxin for treatment of outlet-type constipation. Am J Gastroenterol. 2006 Nov;101(11):2570-5. Epub 2006 Oct 4.</citation>
    <PMID>17029615</PMID>
  </reference>
  <reference>
    <citation>Ron Y, Avni Y, Lukovetski A, Wardi J, Geva D, Birkenfeld S, Halpern Z. Botulinum toxin type-A in therapy of patients with anismus. Dis Colon Rectum. 2001 Dec;44(12):1821-6.</citation>
    <PMID>11742168</PMID>
  </reference>
  <reference>
    <citation>Shafik A, El-Sibai O. Botulin toxin in the treatment of nonrelaxing puborectalis syndrome. Dig Surg. 1998;15(4):347-51.</citation>
    <PMID>9845612</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 25, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 31, 2013</study_first_posted>
  <last_update_submitted>January 28, 2013</last_update_submitted>
  <last_update_submitted_qc>January 28, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 31, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Irvine</investigator_affiliation>
    <investigator_full_name>Samantha Reiter</investigator_full_name>
    <investigator_title>Karen Noblett, MD</investigator_title>
  </responsible_party>
  <keyword>Non relaxing puborectalis syndrome</keyword>
  <keyword>Botulinum toxin A</keyword>
  <keyword>Botox</keyword>
  <keyword>Constipation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>February 5, 2018</submitted>
    <returned>March 6, 2018</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

